Goyal-Honavar Abhijit, Srinivas Dwarakanath, Konar Subhas, Sadashiva Nishanth, Beniwal Manish, Prabhuraj Andiperumal Raj, Arimappamagan Arivazhagan, Rao Kannepalli V L Narasinga, Somanna Sampath
Department of Neurosurgery, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, 560029, India.
Childs Nerv Syst. 2025 Apr 15;41(1):157. doi: 10.1007/s00381-025-06776-7.
Despite the unique challenges presented by pediatric intracranial AVMs, little data is available on the use of GKRS in the pediatric population. Therefore, we aimed to present our experience with GKRS in treating pediatric AVMs, determining the factors that influence nidus obliteration and poor outcomes, with a focus on delayed complications.
This retrospective review examined patients ≤18 years who underwent GKRS between January 2013 and December 2021 for intracranial AVMs. Factors that predicted residual nidus and poor outcomes were analyzed. The utility of AVM size reduction at follow-up in predicting eventual nidus obliteration was tested.
We treated 101 pediatric patients for AVMs with a mean age of 14.2 ± 2.8 years. The mean dose delivered was 22.7 ± 2.4 Gy. After a mean follow-up of 41.4 months, 78 AVMs (77.8%) were obliterated. Residual nidus was associated with prior embolization (HR 4.953; 95% CI 1.343, 18.268; p = 0.016) and age ≥14 years (HR 5.920; 95% CI 1.559, 22.480; p = 0.009) while presentation with bleed (HR 0.178; 95% CI 0.05, 0.631; p = 0.008) was protective. Reduction in size of a nidus during early follow-up closely correlated with eventual obliteration, with increasing accuracy at 6-month, 12-month, and 24-month follow-up (67.6%, 80.2%, and 86.5% respectively). Twelve patients developed perilesional edema, while one patient each developed a chronic encapsulated hematoma (CEH), cyst formation, and rebleed. Dose > 22 Gy (HR 25.641; 95% CI 2.257, 250; p = 0.009) and volume ≥ 3 cc (HR 7.189; 95% CI 1.176, 43.945; p = 0.033) predicted poor outcomes on multivariate analysis.
GKRS delivers a high rate of AVM nidus obliteration in the pediatric population, with prior embolization, older age, and unruptured presentation associated with residual nidus. The incidence of delayed complications, although low, warrants regular surveillance in the pediatric population due to their greater life expectancy.
尽管小儿颅内动静脉畸形(AVM)带来了独特的挑战,但关于伽玛刀放射外科治疗(GKRS)在儿科人群中的应用数据很少。因此,我们旨在介绍我们使用GKRS治疗小儿AVM的经验,确定影响病灶闭塞和不良结局的因素,重点关注延迟并发症。
这项回顾性研究检查了2013年1月至2021年12月期间因颅内AVM接受GKRS治疗的18岁及以下患者。分析了预测残留病灶和不良结局的因素。测试了随访时AVM大小缩小在预测最终病灶闭塞方面的效用。
我们治疗了101例小儿AVM患者,平均年龄为14.2±2.8岁。平均给予的剂量为22.7±2.4 Gy。平均随访41.4个月后,78个AVM(77.8%)闭塞。残留病灶与先前的栓塞治疗(风险比[HR] 4.953;95%置信区间[CI] 1.343,18.268;p = 0.016)和年龄≥14岁(HR 5.920;95% CI 1.559,22.480;p = 0.009)相关,而出血表现(HR 0.178;95% CI 0.05,0.631;p = 0.008)具有保护作用。早期随访期间病灶大小的缩小与最终闭塞密切相关,在6个月、12个月和24个月随访时准确性增加(分别为67.6%、80.2%和86.5%)。12例患者出现病灶周围水肿,1例患者分别出现慢性包裹性血肿(CEH)、囊肿形成和再出血。多因素分析显示,剂量>22 Gy(HR 25.641;95% CI 2.257,250;p = 0.009)和体积≥3 cc(HR 7.189;95% CI 1.176,43.945;p = 0.033)预测不良结局。
GKRS在儿科人群中使AVM病灶的闭塞率很高,先前的栓塞治疗、年龄较大和未破裂表现与残留病灶相关。延迟并发症的发生率虽然很低,但由于儿科人群预期寿命较长,因此有必要进行定期监测。